{
    "clinical_study": {
        "@rank": "111154", 
        "arm_group": {
            "arm_group_label": "Ruxolitinib and Erlotinib", 
            "arm_group_type": "Experimental", 
            "description": "Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.\nPhase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion."
        }, 
        "brief_summary": {
            "textblock": "This is a phase 1 study. The goal of this study is to test the safety of combining the drugs\n      erlotinib and ruxolitinib at different dose levels. The investigators want to find out what\n      effects, good and/or bad, taking erlotinib and ruxolitinib has on the patients and on lung\n      cancer. Erlotinib and ruxolitinib are FDA approved for other indications, but the use of\n      erlotinib and ruxolitinib together has not been studied before and is not FDA-approved."
        }, 
        "brief_title": "Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib", 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologic evidence of advanced (non-operable or metastatic) biopsy-proven stage IV\n             or recurrent lung cancer reviewed at MSKCC.\n\n          -  a documented somatic activating mutation in EGFR (including but not limited to Exon\n             19 deletion or L858R)\n\n          -  Radiographic progression by RECIST 1.1 during treatment with erlotinib. Prior\n             chemotherapy regimens are permitted.\n\n          -  Received erlotinib treatment for at least 1 month prior to enrollment\n\n          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated\n\n          -  Must have undergone biopsy after development of acquired resistance to erlotinib\n             (which is performed as standard of care) with adequate tissue to determine EGFR T790M\n             and tumor histology. Slides from an outside institution may be used.\n\n          -  KPS \u2265 70%\n\n          -  Age>18 years old\n\n          -  Patients must have adequate organ function:\n\n               -  AST, ALT, Alk phos \u2264 3.0 x ULN\n\n               -  Total bilirubin \u2264 2.0 x ULN\n\n               -  Creatinine <2.0 X upper limit of normal and/or a creatinine clearance \u2265 60ml/min\n\n               -  Absolute neutrophil count (ANC) \u22651,000 cells/mm\u00b3.\n\n               -  Platelet count \u2265 100,000/mm\u00b3\n\n               -  Hemoglobin \u2265 9.0g/dL.\n\n        Exclusion Criteria:\n\n          -  Concurrent therapy with a potent CYP3A4 inducer or inhibitor. Subjects may enter\n             screening when therapy with the potent inhibitor or inducer is completed and may\n             begin study treatment after 1 week or 5 half-lives, whichever is longer.\n\n          -  Patients with symptomatic brain metastasis requiring escalating doses of steroids.\n\n          -  Any type of systemic therapy (chemotherapy or experimental drugs) within 3 weeks of\n             starting treatment on protocol except for erlotinib or other EGFR TKI.\n\n          -  Any radiation within 2 weeks prior to starting treatment on protocol\n\n          -  Patients with \u2265 grade 2 or greater diarrhea despite maximal medical management due to\n             medications or a medical condition such as Crohn's disease, malabsorption.\n\n          -  Inadequate recovery from any toxicities related to prior treatment (to Grade 1 or\n             baseline).\n\n          -  Pregnant or lactating women\n\n          -  Patients who have received prior treatment with JAK inhibitor\n\n          -  Previously or current malignancies at other sites within the last 2 years, with the\n             exception of adequately treated in situ carcinoma of the cervix, basal or squamous\n             cell carcinoma of the skin,  prostate cancer that does not require active treatment\n             per National Comprehensive Cancer Network (NCCN) guidelines, superficial bladder\n             cancer or other noninvasive indolent or stage 1 malignancy without sponsor approval.\n\n          -  Clinically significant cardiac disease including unstable angina, acute myocardial\n             infarction within 6 months from Day 1 of study drug administration, New York Heart\n             Association Class III or IV congestive heart failure, or symptomatic arrythmias\n             requiring therapy,\n\n          -  Chronic or current active infections requiring systemic antibiotics, antifungals or\n             antiviral therapy.\n\n          -  Known human immunodeficiency virus infection, or hepatitis B virus (HBV) viremia or\n             hepatitis C virus (HCV) viremia. Screening for the study does not require assessment\n             for these infections if not already known.\n\n          -  Any other condition that, in the opinion of the Investigator, may compromise the\n             safety, compliance of the patient, or would preclude the patient from successful\n             completion of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155465", 
            "org_study_id": "14-043"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ruxolitinib and Erlotinib", 
                "description": "Ruxolitinib 10mg PO BID\nRuxolitinib 15mg PO BID\nRuxolitinib 20mg PO BID", 
                "intervention_name": "Ruxolitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ruxolitinib and Erlotinib", 
                "description": "Erlotinib 150mg PO QD", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ruxolitinib", 
            "Erlotinib", 
            "EGFR-mutant", 
            "14-043"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "Memorial Sloan Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "contact_backup": {
                    "last_name": "Gregory Riely, MD, PhD", 
                    "phone": "646-888-4199"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Helena Yu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center at Phelps"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib", 
        "overall_contact": {
            "last_name": "Helena Yu, MD", 
            "phone": "646-888-4274"
        }, 
        "overall_contact_backup": {
            "last_name": "Gregory Riely, MD, PhD", 
            "phone": "646-888-4199"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Helena Yu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "All patients will receive erlotinib at 150mg orally daily along with doses of ruxolitinib orally twice daily. Patients in dose level 1 will receive erlotinib 150mg orally daily and ruxolitinib 10mg orally twice daily. In dose level 2, patients will receive erlotinib 150mg orally daily and ruxolitinib 15mg orally twice daily. In dose level 3, patients will receive erlotinib 150mg orally daily and ruxolitinib 20mg orally twice daily.", 
                "measure": "maximally tolerated dose (MTD) (Phase I)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Tumor response will be assessed using RECIST 1.1.", 
                "measure": "Assess overall response rate (Phase I)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155465"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Toxicity grading will be performed in accordance with NCI CTCAE, version 4.0.", 
                "measure": "toxicity profile (Phase I)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Overall survival and time to progression will be estimated using the Kaplan-Meier method, with the follow-up starting at the initiation of therapy.", 
                "measure": "survival (Phase II)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}